Richon V M, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind R A, Marks P A
Cell Biology Program, Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10021, USA.
Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3003-7. doi: 10.1073/pnas.95.6.3003.
Hybrid polar compounds (HPCs) have been synthesized that induce terminal differentiation and/or apoptosis in various transformed cells. We have previously reported on the development of the second-generation HPCs suberoylanilide hydroxamic acid (SAHA) and m-carboxycinnamic acid bishydroxamide (CBHA) that are 2,000-fold more potent inducers on a molar basis than the prototype HPC hexamethylene bisacetamide (HMBA). Herein we report that CBHA and SAHA inhibit histone deacetylase 1 (HDAC1) and histone deacetylase 3 (HDAC3) activity in vitro. Treatment of cells in culture with SAHA results in a marked hyperacetylation of histone H4, but culture with HMBA does not. Murine erythroleukemia cells developed for resistance to SAHA are cross-resistant to trichostatin A, a known deacetylase inhibitor and differentiation inducer, but are not cross-resistant to HMBA. These studies show that the second-generation HPCs, unlike HMBA, are potent inhibitors of HDAC activity. In this sense, HMBA and the second-generation HPCs appear to induce differentiation by different pathways.
已合成出能诱导多种转化细胞发生终末分化和/或凋亡的杂合极性化合物(HPCs)。我们之前报道过第二代HPCs,即辛二酰苯胺异羟肟酸(SAHA)和间羧基肉桂酸双羟肟酸(CBHA)的研发情况,它们在摩尔基础上作为诱导剂的效力比原型HPC六亚甲基双乙酰胺(HMBA)高2000倍。在此我们报道,CBHA和SAHA在体外可抑制组蛋白脱乙酰基酶1(HDAC1)和组蛋白脱乙酰基酶3(HDAC3)的活性。用SAHA处理培养中的细胞会导致组蛋白H4显著超乙酰化,但用HMBA培养则不会。对SAHA产生抗性的小鼠红白血病细胞对曲古抑菌素A(一种已知的脱乙酰基酶抑制剂和分化诱导剂)产生交叉抗性,但对HMBA不产生交叉抗性。这些研究表明,与HMBA不同,第二代HPCs是HDAC活性的有效抑制剂。从这个意义上说,HMBA和第二代HPCs似乎通过不同途径诱导分化。